Arvinas Holding Company (ARVN) AI Stock Analysis

• Market Cap: $567.52M
• Dividend Yield: N/A
• Average Volume (3M): 1.90M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 430
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.84
• Shares Outstanding: 73,417,595
• 10 Day Avg. Volume: 1,379,663
• 30 Day Avg. Volume: 1,900,899
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.55
• Enterprise Value/Revenue: -0.84
• Enterprise Value/Gross Profit: -0.84
• Enterprise Value/Ebitda: 2.71
• 1Y Price Target: $13.75
• Price Target Upside: 77.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13

• Rating: 50 Neutral
• Price Target: $7.50 ▼(-2.98% Downside)

Arvinas Holding Company presents a mixed outlook. The most significant factor is its financial performance, which is challenged by ongoing losses and declining revenue. Technical analysis shows a neutral trend, while valuation is weak due to a negative P/E ratio. The earnings call provides some optimism with strategic progress and partnerships, but challenges remain. Overall, the stock score reflects these mixed signals, with financial challenges being the most impactful.

Positive Factors

Pipeline Development

Arvinas noted progress in their LRRK2 program, advancing into patient studies and showing promising initial data confirming pathway engagement.

Regulatory Milestones

Arvinas announced the submission of the first PROTAC NDA for vepdegestrant based on positive Phase 3 VERITAC-2 data.

Negative Factors

Clinical Trial Outcomes

The full data underpinning the filing was mixed at best.

Market Opportunity

The opportunity has been narrowed to 2L+ ESR1m patients, making it a less attractive market opportunity for PFE.

Market Uncertainty

Not building its own sales force introduces uncertainty in terms of where negotiations might head and potential gaps between approval and market launch.

Arvinas Holding Company Business Overview & Revenue Model

Company Description

Arvinas Holding Company (ARVN) is a biopharmaceutical company focused on developing innovative therapies for cancer and other diseases through its proprietary PROTAC technology, which enables the targeted degradation of disease-causing proteins. The company's research and development efforts are primarily centered around oncology, with a portfolio that includes both preclinical and clinical-stage programs aimed at addressing unmet medical needs in various cancer types. Arvinas collaborates with leading pharmaceutical companies to enhance its therapeutic offerings and accelerate the development of its drug candidates.

How the Company Makes Money

Arvinas generates revenue through several key streams, primarily from partnerships and collaborations with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of the drugs developed using Arvinas's technology. Additionally, the company may receive grant funding for specific research initiatives. The success of Arvinas's revenue model heavily relies on the advancement of its therapeutic candidates through clinical trials and into commercialization, as well as the strength and scale of its partnerships in the biopharmaceutical sector.

Arvinas Holding Company Financial Statement Overview

Summary

Arvinas shows strong revenue growth but struggles with profitability and cash flow. The balance sheet is stable with low debt, but negative cash flows highlight operational challenges.

Income Statement

Arvinas Holding Company has shown a significant increase in total revenue with a TTM revenue of $426.9M compared to $263.4M in the previous year, indicating strong growth. However, the company remains unprofitable with negative EBIT and net income, reflecting challenges in managing operational costs and achieving profitability. The gross profit margin is high, but the negative net profit margin highlights the significant expenses outweighing revenues.

Balance Sheet

The balance sheet is relatively stable with a strong equity base and a low debt-to-equity ratio, suggesting prudent financial management. The company maintains a high level of cash and equivalents, which provides a buffer against financial uncertainty. The equity ratio indicates a solid capital structure, which is positive for long-term stability.

Cash Flow

The cash flow statement reveals challenges with negative operating and free cash flows, indicating potential difficulties in sustaining operations without additional financing. Despite this, the company has managed to maintain liquidity through investing activities. The negative free cash flow growth rate suggests that the company is not yet generating sufficient cash from its operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	372.80M	263.40M	78.50M	131.40M	53.60M	25.90M
Gross Profit	371.40M	263.40M	78.50M	131.40M	53.60M	21.80M
EBITDA	-115.70M	-243.60M	-394.80M	-255.00M	-182.40M	-117.60M
Net Income	-72.60M	-198.90M	-367.30M	-282.50M	-191.00M	-119.30M
Balance Sheet
Total Assets	909.30M	1.09B	1.30B	1.27B	1.58B	717.37M
Cash, Cash Equivalents and Short-Term Investments	861.20M	1.04B	1.26B	1.21B	1.50B	688.53M
Total Debt	9.90M	9.70M	3.20M	5.50M	5.00M	4.10M
Total Liabilities	300.00M	529.70M	644.60M	703.90M	799.90M	75.11M
Stockholders Equity	609.30M	561.70M	660.00M	564.90M	781.70M	642.26M
Cash Flow
Free Cash Flow	-399.00M	-261.10M	-350.70M	-280.30M	554.70M	-96.20M
Operating Cash Flow	-396.40M	-259.30M	-347.80M	-273.50M	559.40M	-89.76M
Investing Cash Flow	347.70M	34.70M	203.50M	242.80M	-1.31B	164.25M
Financing Cash Flow	3.30M	7.90M	374.70M	4.70M	278.60M	504.67M

Arvinas Holding Company Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.73
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARVN, the sentiment is Positive. The current price of 7.73 is above the 20-day moving average (MA) of 7.17, above the 50-day MA of 7.48, and below the 200-day MA of 12.54, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 57.65 is Neutral, neither overbought nor oversold. The STOCH value of 73.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARVN.

Arvinas Holding Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NAGE	76 Outperform	$789.55M	46.11	37.36%	―	35.89%	―
PRTC	60 Neutral	$396.20M	9.58	14.26%	―	1263.40%	―
Sector *	51 Neutral	$7.85B	-0.21	-41.41%	2.22%	22.81%	-2.01%
ARVN	50 Neutral	$567.52M	―	-35.41%	―	―	―
IMTX	45 Neutral	$618.69M	53.85	-17.34%	―	83.36%	22.27%
OPT	39 Underperform	$483.16M	―		―	-80.09%	60.25%
SION	―	$1.09B	―		―	―	―

Arvinas Holding Company Corporate Events

Arvinas and Pfizer’s FDA Nod for Cancer Drug

On August 8, 2025, Arvinas, in collaboration with Pfizer, announced that the FDA accepted their New Drug Application for vepdegestrant, a PROTAC ER degrader, for treating ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. This acceptance, based on the Phase 3 VERITAC-2 trial, marks a significant step forward as vepdegestrant demonstrated improved progression-free survival compared to fulvestrant, potentially offering a new treatment option for patients with limited alternatives after first-line therapy.

Arvinas Elects New Directors and Ratifies Auditor

At the annual meeting held on June 25, 2025, Arvinas Holding Company stockholders elected new Class I directors to the board, approved a non-binding advisory proposal on executive compensation, and ratified Deloitte & Touche LLP as the independent accounting firm for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and financial oversight strategies, potentially impacting its operational stability and stakeholder confidence.

Arvinas Unveils Promising ARV-393 Data at EHA Congress

On June 13, 2025, Arvinas, Inc. presented data from preclinical studies of ARV-393, a PROTAC BCL6 degrader, at the European Hematology Association Congress in Milan. The studies showed significant single-agent activity of ARV-393 in models of nodal T-follicular helper cell lymphoma and transformed follicular lymphoma, as well as enhanced antitumor activity in combination with small molecule inhibitors in models of aggressive diffuse large B-cell lymphoma. These findings suggest potential broad utility for ARV-393 across non-Hodgkin lymphoma subtypes and support the exploration of combination strategies, including chemotherapy-free approaches.

Arvinas R&D President Ian Taylor Resigns

On June 4, 2025, Ian Taylor, Ph.D., President of Research and Development at Arvinas, Inc., announced his resignation effective June 6, 2025, to retire. Despite stepping down, Dr. Taylor will continue to contribute to the company by entering a Consulting Agreement to provide advisory services for one year and will remain as chair of the Scientific Advisory Board.

Arvinas and Pfizer Submit New Drug Application

On June 6, 2025, Arvinas, in collaboration with Pfizer, announced the submission of a New Drug Application to the U.S. FDA for vepdegestrant, aimed at treating patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer. This submission follows promising results from the Phase 3 VERITAC-2 clinical trial, which demonstrated the potential of vepdegestrant as a new treatment option, marking a significant step in Arvinas’ efforts to advance cancer therapies and potentially impact the market for breast cancer treatments.

Arvinas and Pfizer Announce Phase 3 Trial Results

On May 31, 2025, Arvinas, Inc. and Pfizer announced detailed results from their Phase 3 VERITAC-2 clinical trial, which evaluated vepdegestrant as a monotherapy for ER+/HER2- advanced or metastatic breast cancer. The trial demonstrated a significant improvement in progression-free survival among patients with ESR1 mutations, with vepdegestrant reducing the risk of disease progression or death by 43% compared to fulvestrant. Despite not reaching statistical significance in the intent-to-treat population, the results suggest vepdegestrant’s potential as a best-in-class treatment option. The companies plan to submit a New Drug Application to the FDA in the latter half of 2025, indicating a significant step towards regulatory approval and potential market introduction.